FDA clears Curetis’ Unyvero LRT for BAL specimens; OPGN shares up

OpGen (NASDAQ:OPGN) is up 13% premarket on the heels of an update on the business of Curetis GmbH.

On December 20, 2019 Curetis has received 510(k) clearance by the FDA to market its Unyvero LRT Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage (BAL) samples to diagnose lower respiratory tract infections such as pneumonia.

OpGen and Curetis entered into merger agreement on September 4, 2019.

https://seekingalpha.com/news/3528086-fda-clears-curetis-unyvero-lrt-for-bal-specimens-opgn-shares-up-13-premarket